|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.0500 - 1.2500|
|52 Week Range||0.9600 - 3.0100|
|Beta (5Y Monthly)||1.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CURE Pharmaceutical Holdings ("CURE" or the "Company") (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans.
CURE Pharmaceutical Closes $10 Million Financing
CURE Pharmaceutical Holding (OTCQB: CURR) wholly owned subsidiary Sera Labs is challenging the status quo of the health and wellness sector by bringing innovative products to market using groundbreaking technology and superior ingredients. As a trusted industry leader that continues to offer consumer solutions, Sera Lab’s is launching the Nutri-Strips brand with a multi-channel advertising and marketing strategy beginning initially with "Sleep A.S.A.P.™," which offers a fast-acting, drug-free solution to America’s sleep problem.